4D Molecular Therapeutics (FDMT)
(Delayed Data from NSDQ)
$13.50 USD
-3.32 (-19.74%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $13.61 +0.11 (0.81%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for 4D Molecular Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 21 | 3 | 18 | 14 | 7 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 21 | 3 | 18 | 14 | 7 |
Selling & Adminstrative & Depr. & Amort Expenses | 134 | 113 | 89 | 70 | 58 |
Income After Depreciation & Amortization | -113 | -110 | -71 | -57 | -51 |
Non-Operating Income | 12 | 3 | 0 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -101 | -107 | -71 | -57 | -49 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -101 | -107 | -71 | -57 | -49 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -101 | -107 | -71 | -57 | -49 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -110 | -107 | -69 | -55 | -50 |
Depreciation & Amortization (Cash Flow) | 3 | 3 | 2 | 1 | 1 |
Income After Depreciation & Amortization | -113 | -110 | -71 | -57 | -51 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 39.13 | 32.35 | 27.73 | 6.43 | NA |
Diluted EPS Before Non-Recurring Items | -2.58 | -3.32 | -2.57 | -8.82 | NA |
Diluted Net EPS (GAAP) | -2.58 | -3.32 | -2.57 | -8.82 | NA |
Fiscal Year end for 4D Molecular Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.01 | 0.03 | -0.02 | 20.20 | 0.24 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.01 | 0.03 | -0.02 | 20.20 | 0.24 |
SG&A, R&D, and Dept/Amort Expenses | 42.46 | 38.16 | 36.63 | 34.18 | 32.37 |
Income After SG&A, R&D, and Dept/Amort Expenses | -42.45 | -38.13 | -36.65 | -13.98 | -32.13 |
Non-Operating Income | 7.50 | 5.74 | 4.37 | 3.72 | 2.52 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -34.95 | -32.40 | -32.28 | -10.26 | -29.62 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -34.95 | -32.40 | -32.28 | -10.26 | -29.62 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -34.95 | -32.40 | -32.28 | -10.26 | -29.62 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 55.28 | 49.27 | 41.93 | 42.26 | 38.43 |
Diluted EPS Before Non-Recurring Items | -0.63 | -0.66 | -0.77 | -0.24 | -0.77 |
Diluted Net EPS (GAAP) | -0.63 | -0.66 | -0.69 | -0.24 | -0.77 |